McKesson raises FY2026 adj. EPS guidance to $38.05-$38.55; long-term growth target increased to 13%-16%

MCKESSON CORP

Fiscal 2026 Adjusted EPS guidance raised and narrowed to $38.05-$38.55 from $37.10-$37.90.
Long-term Adjusted EPS growth target increased to 13%-16% from prior 12%-14%.
New segment long-term growth targets: North American Pharmaceutical 5%-8%, Oncology & Multispecialty 13%-16%, Prescription Technology Solutions 10%-13%.
Medical-Surgical separation and new organizational structure announced on Sept 18, 2025, reaffirmed at Investor Day.
Investor Day webcast on Sept 23, 2025; Q2 FY2026 earnings scheduled for Nov 5, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.